KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in IntangiblesDepreciation & Amortization (CF)Depreciation and DepletionDivestmentsExchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Recursion Pharmaceuticals (RXRX) Shares Issued (2020 - 2025)

Recursion Pharmaceuticals (RXRX) has disclosed Shares Issued for 6 consecutive years, with $525.6 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Shares Issued rose 286.87% year-over-year to $525.6 million, compared with a TTM value of $528.9 million through Dec 2025, up 6394.71%, and an annual FY2025 reading of $528.9 million, up 6394.71% over the prior year.
  • Shares Issued was $525.6 million for Q4 2025 at Recursion Pharmaceuticals, up from -$993000.0 in the prior quarter.
  • Across five years, Shares Issued topped out at $525.6 million in Q4 2025 and bottomed at -$281.2 million in Q4 2024.
  • Average Shares Issued over 5 years is $60.2 million, with a median of $3.3 million recorded in 2023.
  • The sharpest move saw Shares Issued surged 2879768.75% in 2021, then plummeted 8727.12% in 2024.
  • Year by year, Shares Issued stood at $460.7 million in 2021, then tumbled by 99.23% to $3.6 million in 2022, then dropped by 8.63% to $3.3 million in 2023, then tumbled by 8727.12% to -$281.2 million in 2024, then soared by 286.87% to $525.6 million in 2025.
  • Business Quant data shows Shares Issued for RXRX at $525.6 million in Q4 2025, -$993000.0 in Q3 2025, and $2.7 million in Q2 2025.